EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieLeitlinie

Effectiveness of a Wilms tumour treatment guideline adapted to local circumstances in sub‐Saharan Africa: A report from Wilms Africa Phase II—CANCaRe Africa

Diriba Fufa iD, Cecilia Mdoka, Mulugeta Ayalew, Harriet Khofi, Emmanuel Amankwah, Nester Chokwenda, Esubalew Mezgebu, Annelies M C Mavinkurve-Groothuis iD, Steve Kamiza, Beatrice Chikaphonya-Phiri, Mulugeta Wassie, Barnabas Atwiine iD und 15 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31300 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Diriba Fufa und 26 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics and Child Health, Jimma University, Jimma, Ethiopia. Hauptthemen laut MEDLINE: Kidney Neoplasms, Wilms Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: SIOP PARC, Foundation S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Wilms tumour (WT) is one of the cancer types targeted by the Global Initiative for Childhood Cancer (GICC). The objective of this study was to describe the outcomes of Wilms Africa Phase II in sub‐Saharan Africa.

Methods

Wilms Africa Phase II used a comprehensive WT treatment protocol in a multi‐centre, prospective study conducted in eight hospitals in Ethiopia (2), Ghana (2), Malawi, Cameroon, Zimbabwe and Uganda. Eligibility criteria were: age younger than 16 years, unilateral WT, diagnosed between 1 January 2021 and 31 December 2022.

Results

We included 230 WT patients, median age 3 years, 53% male. Median maximum tumour diameter at diagnosis was 13.6 cm and 33% of patients had metastatic disease. Nephrectomy was performed in 71% of patients, of whom 21% had a tumour rupture. Two‐year event‐free survival (EFS) was 41.3% ± 3.9% after a median follow‐up of 17 months (range: 1–33 months), with treatment abandonment considered an event. Treatment abandonment occurred in 26% and death during treatment in 14%. Disease relapse occurred in 10%. Two‐year EFS of the 26 patients who received radiotherapy was 64.5% ± 9.7% with no reported disease relapse.

Conclusion

Patients continue to present late with advanced WT in sub‐Saharan Africa, and their survival is below the 60% GICC target. Prevention of treatment abandonment and treatment‐related mortality remain important. Earlier diagnosis and access to radiotherapy are expected to decrease disease‐related mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsWilms TumorAdolescentChildChild, PreschoolFemaleHumansInfantMaleAfrica South of the SaharaAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFollow-Up StudiesNephrectomyPractice Guidelines as TopicPrognosisProspective StudiesSurvival Rate

Stichwörter der Autor:innen

AfricaWilmsnephroblastomaresource‐limited settingssurvival

Autor:innen und Institutionen

  • Pediatrics and Child Health, Jimma University, Jimma, Ethiopia.
  • CANCaRe Africa, The Collaborative African Network for Childhood Cancer Care and Research, Blantyre, Malawi.
  • Unit of Pediatric Hematology Oncology, University of Gondar Specialized Hospital, Gondar, Ethiopia.
  • Paediatrics and Child Health, Kamuzu University of Health Sciences (KUHeS), Blantyre, Malawi.
  • Child Health, Korle-Bu teaching Hospital Accra, Accra, Ghana.
  • College of Health Sciences, Child and Adolescent Health, University of Zimbabwe, Harare, Zimbabwe.

ORCID-Profile: Diriba Fufa, Annelies M C Mavinkurve-Groothuis, Barnabas Atwiine, Jeannette Parkes, Kathy Pritchard-Jones, Trijn Israels

Förderung

  • SIOP PARC
  • Foundation S

Zitieren

APA

Fufa, D., Mdoka, C., Ayalew, M., Khofi, H., Amankwah, E., Chokwenda, N., Mezgebu, E., Mavinkurve-Groothuis, A. M. C., Kamiza, S., Chikaphonya-Phiri, B., Wassie, M., Atwiine, B., Branchard, M., Gorostegui, M., Parkes, J., Kudowa, E., Eklu, B., Jator, B., Renner, L. A., …, & Israels, T. (2024). Effectiveness of a Wilms tumour treatment guideline adapted to local circumstances in sub‐Saharan Africa: A report from Wilms Africa Phase II—CANCaRe Africa. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31300

Vancouver

Fufa D, Mdoka C, Ayalew M, Khofi H, Amankwah E, Chokwenda N, et al. Effectiveness of a Wilms tumour treatment guideline adapted to local circumstances in sub‐Saharan Africa: A report from Wilms Africa Phase II—CANCaRe Africa. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31300

BibTeX
@article{Fufa2024,
  author = {Fufa, Diriba and Mdoka, Cecilia and Ayalew, Mulugeta and Khofi, Harriet and Amankwah, Emmanuel and Chokwenda, Nester and Mezgebu, Esubalew and Mavinkurve-Groothuis, Annelies M C and Kamiza, Steve and Chikaphonya-Phiri, Beatrice and Wassie, Mulugeta and Atwiine, Barnabas and Branchard, Mushabe and Gorostegui, Maite and Parkes, Jeannette and Kudowa, Evaristar and Eklu, Bernice and Jator, Brian and Renner, Lorna Awo and Borgstein, Eric and Molyneux, Elizabeth and Kouya, Francine and Pritchard-Jones, Kathy and Paintsil, Vivian and Chitsike, Inam and Chagaluka, George and Israels, Trijn},
  title = {Effectiveness of a Wilms tumour treatment guideline adapted to local circumstances in sub‐Saharan Africa: A report from Wilms Africa Phase II—CANCaRe Africa},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31300}
}
Kostenlos starten →